Latest Industry News & Trends
Market Scope provides comprehensive coverage of the ophthalmic market. Our news stories are a combination of public and proprietary content ranging from coverage of international meetings, surgeon survey results and trends, analysis of company financial reports and public medical registries, press releases, and interviews with executives. Register today to receive free weekly email updates, our top data chart, surgeon poll results, and much more. Locked content can be accessed through a subscription to our ophthalmic industry newsletters.
Recently Added News
STAAR Agrees to Leadership Changes Following Failed Acquisition Attempt
STAAR Surgical and Broadwood Partners reported Jan. 15 that STAAR had agreed to several leadership changes, as the phakic IOL maker moves forward from a shareholder revolt that ended Alcon’s attemp...
Formosa Licenses Clobetasol Drops to Samil for South Korea
Taiwan-based Formosa Pharmaceuticals announced Jan. 12 that it had agreed to license to Samil Pharmaceuticals exclusive rights to market clobetasol propionate 0.05% eye drops for postsurgical infla...
Topcon Healthcare Partners with RemoniHealth for Remote Eye Screening
Topcon Healthcare announced Jan. 13 a commercial partnership with RemoniHealth, of White Plains, New York, which provides remote monitoring of eye disease. No financial details were disclosed. Remo...
US FDA Gives Green Light to Trial of Allotex’ Tissue Implant for Presbyopia
Allotex announced Jan. 8 that the US FDA had signed off on its investigational device exemption (IDE) submission, allowing the company to proceed with a trial of Allo-1, its tissue implant technolo...
Ikarovec Signs Option to License IVT Capsid Technology for Use with AMD Gene Therapy
UK-based Ikarovec reported Jan. 6 that it had signed an option agreement for a worldwide license of VectorBuilder’s novel capsid technology for use with IKAR-003, Ikarovec’s gene therapy candidate ...
Bio Usawa Gains Approval for Lucentis Biosimilar in Rwanda, Ghana
African biotech company Bio Usawa announced Jan. 13 that its Lucentis (ranibizumab) biosimilar had received marketing approval in Ghana under the brand name BioUcenta. The company said the approval...
GenSight Gains Compassionate Use Authorization for Lumevoq in France and Israel
GenSight Biologics reported in December 2025 that regulators in France and Israel had granted early access for compassionate use to Lumevoq, the company’s intravitreal gene therapy candidate for Le...
Nanodropper, Now Mu Medical, Plans Combination with Bedo and Viseon
Nanodropper, of Rochester, Minnesota, announced Jan. 9 that it was now operating as Mu Medical and planned to combine with Bedo Solutions and Viseon Labs under the new umbrella. Nanodropper was fou...
US FDA Grants Fast Track Status to Complement’s GA Gene Therapy Candidate
Complement Therapeutics announced Jan. 8 that the US FDA had granted fast track designation to CTx001, a gene therapy candidate targeting geographic atrophy (GA). Fast track status is intended to f...
STAAR Surgical Calls Off Alcon Acquisition Deal after Failed Shareholder Vote
STAAR Surgical reported Jan. 6 that it intended to terminate its acquisition agreement with Alcon, with no termination fee payable by either party. The announcement came minutes after the start of ...
US FDA Gives Green Light to Trial of GenEdit Bio’s Corneal Gene-Editing Candidate
GenEditBio reported on Jan. 5 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of GEB-101, its gene-editing ...
VivaVision Needs Single US Phase III Trial for Uveitis NDA, FDA Says
VivaVision Biotech reported Jan. 6 that minutes from its meeting with the US FDA confirm that its ongoing Phase III study in China can serve as one of the two pivotal trials required to support a U...
Past News Stories
Christopher J. Rapuano, MD, to Use AAO Presidency to Focus on Emergency Eye Care
Christopher J. Rapuano, MD, plans to use his one-year term as president of the American Academy of Ophthalmology (AAO) to focus on improving emergency eye care services in hospital emergency rooms....
NEI Study Shows Gene Variants Don’t Always Lead to IRDs
New findings from researchers at Mass Eye and Ear challenge the traditional concept of certain gene mutations always resulting in vision loss. Instead, their work shows that genes thought to cause ...
Okyo Pharma Appoints Industry Veteran Robert J. Dempsey as CEO
London’s Okyo Pharma announced Jan. 5 that ophthalmic industry veteran Robert J. Dempsey would assume the role of chief executive officer. Gary S. Jacob, PhD, will transition to chief development o...
Lenz Signs Deal with Lunatus for Marketing of Vizz in Middle East
Lenz Therapeutics announced Jan. 5 an exclusive distribution agreement for Dubai’s Lunatus to develop and commercialize the presbyopia drop Vizz in the Middle East region. Under the deal, Lenz, of ...
US FDA Grants Breakthrough Status to Oculis’ Privosegtor for Optic Neuritis
Swiss company Oculis announced Jan. 6 that the US FDA had granted breakthrough therapy designation to Privosegtor, its treatment candidate for optic neuritis. Privosegtor is a peptoid small molecul...
US FDA Rejects Outlook’s Lytenava for a Third Time, Citing Lack of Efficacy Evidence
Outlook Therapeutics reported Dec. 31 that the US FDA had issued a third complete response letter rejecting the company’s biologics license application (BLA) for Lytenava, an ophthalmic formulation...
US FDA Approves Ranibizumab (Lucentis) Biosimilar from Bioeq, Formycon
Swiss company Bioeq announced Dec. 23 that the US FDA had approved its ranibizumab (Lucentis) biosimilar for all the reference product’s indications: wet age-related neovascular macular degeneratio...
US FDA Accepts Viridian’s TED Candidate for Priority Review, Sets PDUFA Date of June 30, 2026
Viridian Therapeutics reported Dec. 22 that the US FDA had accepted its biologics license application (BLA) for veligrotug, the company’s intravenous treatment candidate for thyroid eye disease (TE...
Alvotech, Teva Reach Deal with Regeneron to Bring Eylea Biosimilar to US Market No Later than H2-2026
Alvotech and Teva reported Dec. 19 that they had reached a settlement and license agreement with Regeneron that clears the way for Teva to commercialize AVT06, a biosimilar to Eylea, in the US, if ...
CMS Issues Billing Codes for Cellution’s Allograft, Balance’s Pressure Goggles
The US Centers for Medicare and Medicaid Services (CMS) issued a Q-code in Q3-2025 for Cellution Biologics’ AmchoMatrixDL, an amnion membrane allograft that acts as a barrier and provides protectiv...
US FDA Gives Green Light to Trial of Viatris’ Gene Therapy Candidate for NK
Viatris reported on Dec. 18 that the US FDA had signed off on its investigational new drug (IND) application, allowing the company to proceed with a Phase I/II trial of MR-146, a gene therapy candi...
Virtual Retina Could Help Unlock New Treatments for Vision Loss, Researchers Say
New computer modeling could help scientists better understand how the retina regenerates, opening the door to new treatments for vision loss, researchers from the UK’s University of Surrey say. The...
Want to Read the Full Article?
Already Have an Account?
Register A Corporate Account
A corporate account gives you access to licensed reports and subscriptions, the latest news, a personalized dashboard, and weekly emails with news and data.